Cited by 429PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer TherapiesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Open access

Wander, Seth A., Hennessy, Bryan T., Slingerland, Joyce M.·2011·Journal of Clinical Investigation

Open this paper in CoChat — free account Open PDF

Abstract

Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathways gives us.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci44145

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165

Show all 157 references

Research works printed but not linked: 7

Knowles, 2003, Cancer Res., 63, 7652
Chawla, 2006, J Clin Oncol., 24(suppl), 521s
Colombo, 2007, J Clin Oncol., 25(suppl), 278s
Slomovitz, 2008, J Clin Oncol., 26(suppl), 293s
Carracedo, 2008, J Clin Invest., 118, 3065
Chow LWC, et al. Presented at the 29th Annual San Antonio Breast Cancer Symposium (December 14–17, 2006, San Antonio, Texas, USA), Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer.
Shi, 2002, Cancer Res., 62, 5027

Sorted by citations

Items 201–300 of 429

Combined β-sitosterol and trimetazidine mitigate potassium dichromate-induced cardiotoxicity in rats through the interplay between NF-κB/AMPK/mTOR/TLR4 and HO-1/NADPH signaling pathways
El‐Shoura, E. A. M., Salem, M. A., Ahmed, Y. H., Ahmed, L. K., & Zaafar, D. K. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-27021-1 · Cited by 32
Predicting mTOR Inhibitors with a Classifier Using Recursive Partitioning and Naïve Bayesian Approaches
Wang, L., Chen, L., Liu, Z., Zheng, M., Gu, Q., & Xu, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095221 · Cited by 31
Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor
Shackelford, D. B. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.116323 · Cited by 31
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97
Parzych, K., Chinn, T. M., Chen, Z., Loaiza, S., Porsch, F., Valbuena, G. N., Kleijnen, M. F., Karadimitris, A., Gentleman, E., Keun, H. C., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.373 · Cited by 31
Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1
Chang, H.-H., Young, S. H., Sinnett‐Smith, J. W., Chou, C. E. N., Moro, A., Hertzer, K. M., Hines, O. J., Rozengurt, E., & Eibl, G. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00417.2014 · Cited by 31
New mTOR Targets Grb Attention
Yea, S. S., & Fruman, D. A. (2011) · Science · doi:10.1126/science.1208071 · Cited by 31
Synthesis and evaluation of an injectable everolimus prodrug
Wang, H., Zheng, X., Cai, Z., Ou, Y., Zheng, S., & Zhu, T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.01.069 · Cited by 30
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
Fujishita, T., Kojima, Y., Kajino‐Sakamoto, R., Taketo, M. M., & Aoki, M. (2017) · Oncogene · doi:10.1038/onc.2017.242 · Cited by 30
Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer‐signaling PI3K/AKT/mTOR pathway
Rehan, M., & Bajouh, O. S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27100 · Cited by 30
Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches
Renoir, J. (2012) · Steroids · doi:10.1016/j.steroids.2012.07.019 · Cited by 31
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation
Xu, X., Sun, J. F., Song, R., Doscas, M. E., Williamson, A. J., Zhou, J., Sun, J., Jiao, X., Liu, X., & Li, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16737 · Cited by 30
Exploiting the mTOR paradox for disease prevention
Iglesias‐Bartolomé, R., & Gutkind, J. S. (2012) · Oncotarget · doi:10.18632/oncotarget.712 · Cited by 30
Successful Prenatal Treatment of Cardiac Rhabdomyoma in a Fetus with Tuberous Sclerosis
Will, J. C., Siedentopf, N., Schmid, O., Gruber, T. M., Henrich, W., Hertzberg, C., & Weschke, B. (2023) · Pediatric Reports · doi:10.3390/pediatric15010020 · Cited by 29
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
Zatelli, M. C., Fanciulli, G., Malandrino, P., Ramundo, V., Faggiano, A., Colao, A., & _, _. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0413 · Cited by 29
Gastric cardia adenocarcinoma microRNA profiling in Chinese patients
Gao, S., Zhou, F., Zhao, C., Ma, Z., Jia, R., Liang, S., Zhang, M., Zhu, X., Zhang, P., Wang, L., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-4824-5 · Cited by 29
mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro
Ayuk, S. M., & Abrahamse, H. (2019) · Cells · doi:10.3390/cells8050431 · Cited by 30
NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets
Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 31
Autophagy: a new therapeutic target in cartilage injury and osteoarthritis.
Lotz, M., & Caramés, B. (2012) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-20-04-261 · Cited by 31
Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis
Patil, S. A., Bshara, W., Morrison, C., Chandrasekaran, E. V., Matta, K. L., & Neelamegham, S. (2014) · Glycoconjugate Journal · doi:10.1007/s10719-014-9548-4 · Cited by 29
The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Li, J., Zhu, J., Cao, B., & Mao, X. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990638 · Cited by 28
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
O'Regan, R. M., & Paplomata (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s30349 · Cited by 29
FK506-binding protein 12 ligands: a patent review
Liu, F., Wang, Y., Meng, L., Gu, M., & Tan, R. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.828695 · Cited by 29
Nanotechnology-Based Targeting of mTOR Signaling in Cancer
Yoon, M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254574 · Cited by 35
Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy.
Gabani, M. H., Castañeda, D., Nguyen, Q. M., Choi, S. K., Chen, C., Mapara, A., Kassan, A., González, A. A., Khataei, T., Ait‐Aissa, K., et al. (2021) · Europe PMC (PubMed Central) · doi:10.7759/cureus.18194 · Cited by 57
Targeting mitophagy for depression amelioration: a novel therapeutic strategy
Xu, W., Gao, W.-P., Guo, Y., Feng, X., Di, L., Fang, S., Fan, L., He, Y., Zhou, Y., Xie, X., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1235241 · Cited by 30
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas
Feng, W., Liu, Y., Bellail, A. C., Olson, J. J., Sun, S. Y., Lu, G., Ding, L., Yuan, C., Wang, G., & Hao, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.005 · Cited by 28
Activity and complexes of mTOR in diffuse large B-cell lymphomas—a tissue microarray study
Sebestyén, A. R., Sticz, T. B., Márk, Á., Hajdu, M., Tímár, B., Nemes, K., Nagy, N., Váradi, Z., & Kopper, L. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.141 · Cited by 28
Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase
Masola, V., Zaza, G., Granata, S., Gambaro, G., Onisto, M., & Lupo, A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-292 · Cited by 28
1 T moderate intensity static magnetic field affects Akt/mTOR pathway and increases the antitumor efficacy of mTOR inhibitors in CNE-2Z cells
Zhang, L., Yang, X., Liu, J., Luo, Y., Li, Z., Ji, X., Wang, W., & Zhang, X. (2015) · 中国科学通报：英文版 · doi:10.1007/s11434-015-0950-5 · Cited by 27
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma
Milosevic, Z. C., Banković, J., Dinić, J., Tsimplouli, C., Sereti, E., Dragoj, M., Paunović, V., Milovanović, Z., Stepanović, M., Tanić, N., et al. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0380-x · Cited by 27
Targeting myeloid cells to improve cancer immune therapy
Chen, H., Xu, Z., & Varner, J. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1623436 · Cited by 26
A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
Gore, L., Trippett, T. M., Katzenstein, H. M., Boklan, J., Narendran, A., Smith, A., Macy, M. E., Rolla, K., Narashimhan, N., Squillace, R. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3166 · Cited by 26
Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Cirstea, D. D., Santo, L., Hideshima, T., Eda, H., Mishima, Y. M., Nemani, N., Mahindra, A. K., Yee, A. J., Görgün, G., Hu, Y., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0147 · Cited by 26
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Chanal, M., Chevallier, P., Raverot, V., Fonteneau, G., Lucia, K. E., Garcia, J. L. M., Rachwan, A., Jouanneau, E., Trouillas, J., Honnorat, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0891 · Cited by 26
Phosphoinositide 3‐kinase: a new kid on the block in vascular anomalies
Castillo, S. D., Vanhaesebroeck, B., & Sebire, N. J. (2016) · The Journal of Pathology · doi:10.1002/path.4802 · Cited by 24
Revisiting mTOR inhibitors as anticancer agents
Teng, Q., Ashar, Y. V., Gupta, P., Gadee, E., Fan, Y., Reznik, S. E., Wurpel, J. N. D., & Chen, Z. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.030 · Cited by 28
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus
Yates, D. H. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1148603 · Cited by 25
Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice
Kurdi, A., Doncker, M. D., Leloup, A. J. A., Neels, H. M., Timmermans, J., Lemmens, K., Apers, S., Meyer, G. R. Y. D., & Martinet, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13626 · Cited by 27
Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
Posada, I. M. D., Lectez, B. L. P., Sharma, M., Oetken-Lindholm, C., Yetukuri, L., Zhou, Y., Aittokallio, T. A., & Abankwa, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17819 · Cited by 24
Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition
Jin, H., Lee, Y.-H., Park, J.-A., Kim, J. H., Hong, S.-E., Kim, H., Kim, E., Noh, W. C., Kim, B., Ye, S., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.01.086 · Cited by 24
Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma
Zhang, N., Liu, X., Liu, L., Deng, Z., Zeng, Q., Pang, W., Liu, Y., Song, D., & Deng, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0309-3 · Cited by 24
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Sammons, S. L., Kornblum, N. S., & Blackwell, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0587-9 · Cited by 24
Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme
Yao, W., Gong, H., Mei, H., Shi, L., Yu, J., & Hu, Y. (2021) · Journal of Oncology · doi:10.1155/2021/5560915 · Cited by 24
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 27
Chemical and biological basis for development of novel radioprotective drugs for cancer therapy
Checker, R., Patwardhan, R. S., Jayakumar, S., Maurya, D. K., Bandekar, M., Sharma, D., & Sandur, S. K. (2021) · Free Radical Research · doi:10.1080/10715762.2021.1876854 · Cited by 25
Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling
Chen, T., Yuan, Z., Lei, Z., Duan, J., Xue, J., Lu, T., Yan, G., Zhang, L., Liu, Y., Li, Q., et al. (2022) · Theranostics · doi:10.7150/thno.75936 · Cited by 24
Novel Library of Selenocompounds as Kinase Modulators
Plano, D., Ibáñez, E., Calvo, A., Palop, J. A., & Sanmartín, C. (2011) · Molecules · doi:10.3390/molecules16086349 · Cited by 23
Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
Yi, Z., & Ma, F. (2017) · Journal of Breast Cancer · doi:10.4048/jbc.2017.20.4.321 · Cited by 23
The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors
Batukbhai, B. D. O., & Jesus‐Acosta, A. D. (2018) · Pancreas · doi:10.1097/mpa.0000000000001189 · Cited by 23
Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma
Wang, Z., Zheng, T., Wu, Q., WANG, J., Wu, C., & Wang, J. (2011) · Neoplasma · doi:10.4149/neo_2012_018 · Cited by 23
Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells
Sharma, A., Janocha, A. J., Hill, B. T., Smith, M. R., ERZURUM, S. C., & Almasan, A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0124 · Cited by 23
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Almstedt, K., & Schmidt, M. (2015) · Breast Care · doi:10.1159/000405017 · Cited by 22
FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
Singh, M., Leasure, J. M., Chronowski, C., Geier, B., Bondra, K. M., Duan, W., Hensley, L. A., Villalona-Calero, M. A., Li, N., Vergis, A. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0556 · Cited by 22
Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors
Harter, P. N., Jennewein, L., Baumgarten, P., Ilina, E. I., Burger, M. C., Thiepold, A., Tichy, J., Zörnig, M., Senft, C., Steinbach, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127123 · Cited by 23
Regulation of the mTOR-Rac1 axis in platelet function
Aslan, J. E., & McCarty, O. J. T. (2012) · Small GTPases · doi:10.4161/sgtp.19137 · Cited by 22
OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma
Peng, K., Ke, Y., Zhao, Q., Tian, F., Liu, H., Hou, G., & Lu, Z. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.05.013 · Cited by 20
Molecular typing guiding treatment and prognosis of endometrial cancer
Tabata, J., Takenaka, M., & Okamoto, A. (2023) · Gynecology and Obstetrics Clinical Medicine · doi:10.1016/j.gocm.2023.01.011 · Cited by 20
Inhibition of m TOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation
Sun, D., Zhang, Y., Tian, X., Chen, Y., & Fang, J. (2013) · Cell Biology International · doi:10.1002/cbin.10179 · Cited by 20
PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival
Rogers, H. A., Mayne, C. M., Chapman, R. J., Kilday, J., Coyle, B., & Grundy, R. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0222 · Cited by 20
Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma
Xu, D., Toyoda, H., Qi, L., Morimoto, M., Hanaki, R., Iwamoto, S., Komada, Y., & Hirayama, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.143 · Cited by 20
The association between autosomal dominant polycystic kidney disease and cancer
Sun, K., Xu, D., & Mei, C. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1951-5 · Cited by 20
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary
Jarzabek, M. A., Sweeney, K. J., Evans, R. L., Jacobs, A. H., Stupp, R., O’Brien, D. F., Berger, M. S., Prehn, J. H. M., & Byrne, A. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.004 · Cited by 19
A review of the endocrine resistance in hormone-positive breast cancer.
Chien, T.-J. (2021) · PubMed · Cited by 22
Autophagy in alzheimer disease pathogenesis and its therapeutic values
Angst, G., Jia, N., Esqueda, L. T., Fan, Y., Cai, Q., & Wang, C. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2471677 · Cited by 22
A theoretical insight in interactions of some chemical compounds as mTOR inhibitors
Arthur, D. E., Akoji, J. N., Sahnoun, R., Okafor, G. C., Abdullahi, K. L., Abdullahi, S. A., & Mgbemena, C. (2021) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-021-00525-x · Cited by 19
Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery
Fu, Z., Lin, Z., Yang, M. S., & Li, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.706861 · Cited by 18
Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro
Masola, V., Carraro, A., Zaza, G., Bellin, G., Montin, U., Violi, P., Lupo, A., & Tedeschi, U. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0347-6 · Cited by 18
Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas
Maniscalco, L., Millán, Y., Iussich, S., Denina, M., Sánchez‐Céspedes, R., Gattino, F., BIOLATTI, B., Sasaki, N., Nakagawa, T., Renzo, M. F. D., et al. (2013) · BMC Veterinary Research · doi:10.1186/1746-6148-9-80 · Cited by 18
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
Hsu, P.-Y., Wu, V. S., Kanaya, N., Petrossian, K., Hsu, H.-K., Nguyen, D. M., Schmolze, D. B., Kai, M., Liu, C., Lu, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1983 · Cited by 18
Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
Jin, H., Wu, G., Wu, G., & Bao, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8178 · Cited by 18
Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment
Dong, S., Ruiz‐Calderon, B., Rathinam, R., Eastlack, S. C., Maziveyi, M., & Alahari, S. K. (2019) · International Journal of Cancer · doi:10.1002/ijc.32690 · Cited by 18
Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer
Krieger, K. L., Hu, W., Ripperger, T. J., & Woods, N. T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235876 · Cited by 18
The expanding relevance of nuclear mTOR in carcinogenesis
Back, J. H., & Kim, A. L. (2011) · Cell Cycle · doi:10.4161/cc.10.22.18329 · Cited by 18
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells
Yang, Y., Chan, J. Y., Temiz, N. A., & Yee, D. (2018) · Hormones and Cancer · doi:10.1007/s12672-018-0343-8 · Cited by 18
P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity
Jalota‐Badhwar, A., Bhatia, D. R., Boreddy, S. R., Joshi, A., Magesh, V., Desai, N., Chaudhari, S. K., Bose, J. S., Kolla, L. S., Deore, V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0486 · Cited by 17
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Sehdev, A., Karrison, T. G., Zha, Y., Janisch, L. A., Turcich, M., Cohen, E. E. W., Maitland, M. L., Polite, B. N., Gajewski, T. F., Salgia, R., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3619-3 · Cited by 17
Protein kinase inhibitors against malignant lymphoma
D’Cruz, O. J., & Uckun, F. M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780031 · Cited by 17
Inhibitors of K-Ras Plasma Membrane Localization
Cho, K.-J., van der Hoeven, D., & Hancock, J. F. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00011-7 · Cited by 16
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies
Ree, A. H., Flatmark, K., Sælen, M. G., Folkvord, S., Dueland, S., Geisler, J., & Redalen, K. R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.003 · Cited by 15
Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell.
Wang, Y.-D., Su, Y.-J., Li, J., Yao, X.-C., & Liang, G.-J. (2015) · PubMed Central · Cited by 15
Rictor Negatively Regulates High-Affinity Receptors for IgE-Induced Mast Cell Degranulation
Smrž, D., Cruse, G., Beaven, M. A., Kirshenbaum, A. S., Metcalfe, D. D., & Gilfillan, A. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303495 · Cited by 15
Cancer metabolism: targeting cancer universality
Kim, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0551-5 · Cited by 14
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma
Mei, L., Sun, H., Yan, Y., Ji, H., Su, Q., Chang, L., & Wang, L. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.95894 · Cited by 15
N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells
Wang, M., Zhou, A., An, T., Kong, L., Yu, C., Liu, J., Xia, C., Zhou, H., & Li, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0315-1 · Cited by 14
Resistance to Therapy
Rivera, G. A., & Wakelee, H. A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_9 · Cited by 14
Therapies targeting the signal pathways of pheochromocytoma and paraganglioma
Liu, Y., Liu, L., & Zhu, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s219056 · Cited by 14
Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways
Bian, Y., Wu, H., Jiang, W., Kong, X., Xiong, Y., Zeng, L.-H., Zhang, F., Song, J., Wang, C., Yang, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17397 · Cited by 13
A screening strategy for the discovery of drugs that reduce C/EBPβ-LIP translation with potential calorie restriction mimetic properties
Zaini, M. A., Müller, C., Ackermann, T., Reinshagen, J., Kortman, G., Pleß, O., & Calkhoven, C. F. (2017) · Scientific Reports · doi:10.1038/srep42603 · Cited by 14
Simultaneous activation of Kras–Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway
Namikawa, M., Fukuda, A., Mizukoshi, K., Iwane, K., Kawai, M., Yamakawa, G., Omatsu, M., Sono, M., Masuda, T., Araki, O., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6139 · Cited by 13
Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells
Guimarães, I. D. S., Tessarollo, N. G., Junior, P. C. M. L., dos Santos, D. Z., Zampier, R. C., de Oliveira, L. F. R. L., Siqueira, K. V., Silva, I. V., & Rangel, L. B. A. (2015) · InTech eBooks · doi:10.5772/61676 · Cited by 13
JAK2-STAT5 signaling
Yeh, J., Toniolo, P. A., & Frank, D. A. (2013) · JAK-STAT · doi:10.4161/jkst.24635 · Cited by 13
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Momcilovic, M., Bailey, S. T., Lee, J. T., Zamilpa, C., Jones, A. E., Abdelhady, G., Mansfield, J. R., Francis, K. P., & Shackelford, D. B. (2018) · Journal of Visualized Experiments · doi:10.3791/57167 · Cited by 13
Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells
Murase, Y., Hosoya, K., Sato, T., Kim, S., & Okumura, M. (2022) · Oncology Reports · doi:10.3892/or.2022.8272 · Cited by 12
iTRAQ-based proteomic identification of proteins involved in anti-angiogenic effects of Panduratin A on HUVECs
Lai, S.-L., Wong, P., Lim, T. K., Lin, Q., & Mustafa, M. R. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.11.016 · Cited by 12
NOP14-mediated ribosome biogenesis is required for mTORC2 activation and predicts rapamycin sensitivity
Xiao, Y., Kuang, B., Ma, S., Wang, R., Lin, J., Zeng, Y., Xie, X., & Feng, L. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105681 · Cited by 11
Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy
Tang, H., Dilimulati, D., Yang, Z., Zhou, K., Chen, X., Sun, R., Wang, N., Liang, Z. T., Bian, S., Zhao, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105099 · Cited by 14
Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition
Zuber, J., Hermine, O., Chatenoud, L., & Legendre, C. M. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834c237a · Cited by 11
The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review
Zhang, S., Liang, L., Ji, Y., Wang, Z., & Zhou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21832 · Cited by 11
Allosteric therapies for lung cancer
Ye, L., Jing, M., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9567-z · Cited by 12

Authors: Wander, S. A., Hennessy, B. T., & Slingerland, J. M.
Affiliations: University of Miami (US)
Royal College of Surgeons in Ireland (IE)
Corresponding author: Slingerland, Joyce M.
ORCID: Wander, Seth A.
Hennessy, Bryan T.
Slingerland, Joyce M.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2011-04-01
Volume: 121
Issue: 4
Pages: 1231-1241
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci44145
PMC: PMC3069769
OpenAlex: W2025935112
Cited by: 427
References: 157
Citations by year: 2026: 7 · 2025: 17 · 2024: 10 · 2023: 18 · 2022: 16 · 2021: 14 · 2020: 23 · 2019: 23 · 2018: 27 · 2017: 39 · 2016: 28 · 2015: 63 · 2014: 51 · 2013: 47 · 2012: 28
FWCI: 4.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Funders: Doris Duke Charitable Foundation
National Institutes of Health (5-R01-)
National Cancer Institute (5-R01-CA-105118-04, R01CA105118)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: mTOR inhibitors, mTOR signaling, mTORC1, mTORC2, PI3K-related kinases, cancer therapy, therapeutic target
MeSH terms: Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents, Clinical Trials as Topic, Female, Humans, Male, Neoplasms, Transcription Factors, Signal Transduction, Phosphatidylinositol 3-Kinases, Sirolimus, Tumor Suppressor Proteins, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks